S2 Ep35: Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

PER Podcast Sessions

Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

1M ago 28:30

MP3•Episode home

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description
In this podcast, experts Mohamad Mohty, MD, PhD and Surbhi Sidana, MD discuss recent advances in treatment options for relapsed/refractory multiple myeloma (R/R MM).
Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Analyze efficacy and safety data from pivotal trials evaluating new and emerging therapies for relapsed/refractory multiple myeloma (R/R MM)

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AbbVie, Inc.
Faculty:

Mohamad Mohty, MD, PhD
Professor of Hematology
Head of the Hematology and Cellular Therapy Department, Saint-Antoine
Hospital
Sorbonne University
Paris, France
Disclosures: Consulting Fees: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Novartis, Pfizer, Sanofi, Stemline, Takeda; Grants and contracts from an entity: Janssen, Novartis, Sanofi; Manuscript writing or educational events: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Payment or honoraria for lectures: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Presentations: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Speakers’ Bureau: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda.

Surbhi Sidana, MD
Associate Professor of Medicine
Director, Myeloma Disease Focused Group
Division of BMT & Cell Therapy
Stanford University
Stanford, CA
Disclosures: Consulting or Advisory role: AbbVie, Arcellx, Bioline, Bristol Myers Squibb, Genentech, Janssen, Kite, Legend, Pfizer, Regeneron, Roche, Sanofi, Takeda; Research funding: Allogene Therapeutics, Bristol Myers Squibb, Janssen, Magenta Therapeutics, Novartis.

Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an artificial intelligence tool.

To learn more about this topic, including information on strategies for balancing disease- and patient-specific factors in early relapsed multiple myeloma (MM) treatment plans, evidence-based strategies to select and sequence T-cell therapies for heavily pretreated patients with relapsed/refractory (R/R) MM, and proactive measures to mitigate treatment-related toxicities in patients with R/R MM, go to https://www.gotoper.com/aom-25-rrmm-full-archive-activity

Release Date

July 30, 2025
Expiration Date

July 30, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

60 episodes

#Science #Biology #Podcasting Education #Medicine #Spectives